Guidelines for immunosuppressive therapy
• Effective
• Many routes of administration
• Redistribution of white blood cells
o Lymphopenia
o Neutrophilia
• Decreased vascular permeability
• Monocyte/macrophage function modulation
o Reduced cytokine production
o Phagocytosis inhibited
• Antibody production only reduced with long-term aggressive therapy
• Most side effects are bothersome, but not dangerous to the patient
o Panting
o Thin skin
o Liver value elevation
o Polyphagia
o Pot belly
• PU/PD one of the most bothersome for the owners, consider DDAVP (1-2 drops BID, adjust dose to control signs)
• When serious side effects occur they are bad
o Colonic ulcers with spinal disease
o Although gastric changes are common with high dose therapy it does not seem to be a clinical problem
• PTE
• Pancreatitis
• Nitrogen mustard derivative
• Alkylating agent
o Cytoxic to resting and dividing cells
o Also chemo drug
• Inexpensive
• Commonly used as adjunctive therapy
• Cross links DNA to prevent replication of cells
• More pronounced in B lymphocytes (AB producers)
• Phagocytosis may also be inhibited
• Some question efficacy in immune-mediated disease, especially IMHA
• Relatively rare, but when they occur they can be serious
•GI signs (rare)
• Bone marrow suppression (rare, but monitor CBCs regularly)
• Sterile cystitis (monitor UAs)
o Make sure patient is drinking lots and urinating frequently (usually not a problem since many are on glucocorticoids concurrently, if it does occur it is a tough one to deal with
• Usually 50 mg/M2 is used daily for 4 days, stop 3 days and then repeat therapy
• Every other day therapy is also possible
• I rarely use long term and now use it mainly for chemo
• Can be used in cats, not very safe though
• Relatively inexpensive
• Used as an adjunctive therapy (cut pred faster)
• Side effects very rare, but when they happen they are bad
• My favorite adjunctive therapy with immune-mediated disease
• Antimetabolite, mainly effects proliferating T-cells
• Antibody production reduced, however not by influencing the B-cells, seems to be a reduction in T-helper cells
• Quite rare
• Bone marrow suppression can occur (may be a genetic thing, it is in humans)
o Monitor CBCs
• Pancreatitis can occur
• Hepatopathies can occur as well
o Monitor chemistry panels
• Start at 2 mg/kg initially daily for 7 days
• Reduce to 0.5 to 1 mg/kg every other day
• Use in conjunction with other medications, especially glucocorticoids
• Effect may take 2 to 4 weeks to set in
• May be a very good drug in IMHA
• Avoid in cats
• Can be used in dogs and cats
• Expensive
• Effective and potent
• Predominantly influences T-lymphocytes
• Reduces cytokine production
• Reduces the amplification signals that activate macrophages
• Mainly used for transplant patients in humans
• In veterinary medicine has shown benefit in KCS, perianal fistulas, IMHA and preventing transplant rejection
• Gingival hyperplasia
• Renal disease not an issue in small animals unless overdosed
• GI upset especially with liquid
• Potent enough to allow secondary infections to occur
• Every patient is different, monitoring trough levels recommended though at least in dogs with pruritus drug levels do not correlate with response
• Neoral better than Sandimmune (variable, but up to 10 times the blood levels)
• 10 to 20 mg/kg/day (regular cyclosporine) effective for perianal fistulas
• Usually use Neoral in dogs at 5 mg/kg BID initially, monitor trough 24 to 48 hours after starting therapy
• Ketoconazole at 10 mg/kg SID reduces amount of cyclosporine needed
• In cats the dosage is 0.5 to 2.5 mg/kg Neoral BID, also check trough after 24 to 48 hours of therapy
• Since there are various ways to measure cyclosporine check with the lab as to what levels are desirable
• Cool drug, amazing efficacy with IMT and IMHA
• In IMHA mortality unchanged or possibly even worse
• Extremely expensive and often impossible to get a hold of
• Dose is 0.5 to 1 gram/kg in dogs
• Anabolic steroid
• May have some questionable efficacy in immune-mediated blood dyscrasias
• Long onset of action
• Expensive
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen